Cyclophosphamide treatment of MS: Current therapeutic approaches and treatment regimens

International MS Journal

Volumn 17, Issue 1, 2010, Pages 12-18

  Elkhalifa, A S ^a   Weiner, H L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cyclophosphamide; Immunosuppression; Multiple sclerosis

Indexed keywords

BETA INTERFERON; CORTICOTROPIN; CYCLOPHOSPHAMIDE; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 4; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; PREDNISONE; STEROID; TRANSFORMING GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT;

ALOPECIA; AMENORRHEA; ARTICLE; BLADDER DISEASE; CANCER RISK; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; INFERTILITY; LEUKOENCEPHALOPATHY; LEUKOPENIA; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PLASMAPHERESIS; SIDE EFFECT; TH1 CELL; TH17 CELL; VOMITING; CHEMICALLY INDUCED; LUPUS ERYTHEMATOSUS NEPHRITIS; TREATMENT OUTCOME;

CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERFERON-BETA; INTERLEUKIN-10; LUPUS NEPHRITIS; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 77954851581     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophos-phamide therapy. Ann Intern Med 1993;119:366-369
2. Brannagan TH. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immunemediated neuropathies. Neurology 2003; 59:S33-40.
3. Brannagan TH, Pradhan A, Heiman-Patterson T, Winkelman AC, Styler MJ, Topolsky DL, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002; 58:1856-1858
4. Martin R, McFarland HF, and McFarlin, DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10:153-187
5. Hafler, DA, and Weiner HL. Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev 1995; 144:75-107
6. Conlon P, Oksenberg JR, Zhang J and Steinman, L. The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system. Neurobiol Dis 1999; 6:149-166
7. La Mantia L, Milanese C, Mascoli C, D'Amico R, and Weinstock- Guttman B. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev 2007 CD002819.
8. Aimard G, Girard PF and Raveau J. [Multiple sclerosis and the autoimmunization process. Treatment by antimitotics]. Lyon Med 1966; 215:345-352
9. Weiner HL, and Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002; 8:142-154
10. Girard PF, Aimard G, and Pellet H. 1967. [Immunodepressive therapy in neurology]. Presse Med 75:967-968
11. Hommes OR, Prick JJ, and Lamers KJ. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophos-phamide and prednisone. Clin Neurol Neurosurg 1975; 78:59-72
12. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308:173-180
13. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43:910-918
14. Likosky WH, FiremanB, Elmore R, Eno G, Gale K, Goode GB, et al. Intense immuno-suppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 1991; 54:1055-1060
15. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 1991; 337:441-446
16. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46:296-304
17. Gobbini MI, Smith ME, Richert ND, Frank JA, and McFarland HF. 1999. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsingremitting multiple sclerosis. J Neuroimmunol 1999; 99:142-149
18. Weinstock-Guttman B, Kinkel RP, Cohen JA, Ransohoff RM, Schwetz K, Gogol D, et al. Treatment of Fulminant Multiple Sclerosis With Intravenous Cyclophosphamide. The Neurologist 1997; 3:178-175
19. Hohol MJ, Olek MJ, Orav EJ, Stazzone L, Hafler DA, Khoury SJ, et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/ methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler 1999; 5:403-409
20. Khan OA, Zvartau-Hind M, Caon C, Din MU, Cochran M, Lisak D. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 2001; 7:185-188
21. Perini P, and Gallo P. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. J Neurol 2003; 250:834-838
22. Zephir H, de Seze J, Duhamel A, Debouverie M, Hautecoeur P, Lebrun C, et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004; 218:73-77
23. Patti F, Amato MP, Filippi M, Gallo P, Trojano M, and Comi GC. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J Neurol Sci 2004; 223:69-71
24. Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 2005; 11:573-582
25. Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 2006; 63:1388-1393
26. Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008; 65:1044-1051
27. Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, and Chitnis T. 2009. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009; 72:2076-2082
28. Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year followup observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008; 79:52-56
29. Patti F, Lo Fermo S, D'Amico E, Messina S, Cavallaro T, and Zappia M. Comparison of Two Therapeutic Strategies in Active Relapsing-Remitting MS: Cyclophosphamide as Induction for 12 Months Followed by Interferon Beta Versus Interferon Beta. A 2-Year Randomized Trial. AAN 61st Annual Meeting April-May 2009, Poster Session VII: Multiple Sclerosis: Therapeutics II
30. Perumal JS, Hreha S, Caon C, Bao F, Penmesta R, Tselis A, et al. Long-Term Efficacy and Safety of Intense Immunosuppression as First Line Therapy in Clinically Active Relapsing MS: A New Treatment Algorithm. AAN 61st Annual Meeting April-May 2009, Poster Session VII: Multiple Sclerosis: Therapeutics II.
31. Perini P, Ranzato F, Calabrese M, Battistin L, and Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77:953-955
32. Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, and Amato MP. 2008. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. J Neurol Sci 2008; 266:25-30
33. Paterson PY, and Drobish DG. Cyclophosphamide: effect on experimental allergic encephalomyelitis in Lewis rats. Science 1969; 165:191-192
34. Moody DJ, Fahey JL, Grable E, Ellison GW, and Myers LW. Administration of monthly pulses of cyclophosphamide in multiple sclerosis patients. Delayed recovery of several immune parameters following discontinuation of longterm cyclophosphamide treatment. J Neuroimmunol 1987; 14:175-182
35. Moody DJ, Kagan J, Liao D, Ellison GW, and Myers LW. Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of longterm treatment on immunologic parameters. J Neuroimmunol 1987; 14:161-173
36. Hafler, D.A., J. Orav, R. Gertz, L. Stazzone, and H.L. Weiner. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol 1991; 32:149-158
37. Mickey MR, Ellison GW, Fahey JL, Moody DJ, and Myers LW. 1987. Correlation of clinical and immunologic states in multiple sclerosis. Arch Neurol 1987; 44:371-375
38. Smith, D.R., K.E. Balashov, D.A. Hafler, S.J. Khoury, and H.L. Weiner. Immune deviation following pulse cyclophosphamide/ methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 1997; 42:313-318
39. Comabella M, Balashov K, Issazadeh S, Smith D, Weiner HL, and Khoury SJ. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998; 102:671-678
40. Balashov KE, Smith, DR Khoury SJ, Hafler DA, and Weiner HL. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A 1997; 94:599-603
41. Karp CL. Interleukin-12: amiss in MS. Ann Neurol 1999; 45: 689-692
42. Weiner HL. Immunosuppressive treatment in multiple sclerosis. J Neurol Sci 2004; 223:1-11
43. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65:239-248
44. Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler 2005;11:573-582
45. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, and Weiner HL. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 2009; 10:958-964
46. Karni A, Balashov K, Hancock WW, Bharanidharan P, Abraham M, Khoury SJ, et al. Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFNgamma production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol 2004; 146:189-198
47. Hommes OR, Aerts F, Bahr U, and Schulten HR. Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression. J Neurol Sci 1983; 58:297-303
48. Bahr U, Schulten HR, Hommes OR, and Aerts F. Determination of cyclophosphamide in urine, serum and cerebrospinal fluid of multiple sclerosis patients by field desorption mass spectrometry. Clin Chim Acta 1980; 103:183-192
49. Wender M, Tokarz E, Michalowska G, and Wajgt A. Therapeutic trials of multiple sclerosis and intrathecal IgG production. Ital J Neurol Sci 1986; 7:205-208
50. Lamers KJ, Uitdehaag BM, Hommes OR, Doesburg W, Wevers RA, and von Geel WJ. The short-term effect of an immunosupp-ressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1988; 51:1334-1337